BETHLEHEM, Pa., Dec. 7, 2010 /PRNewswire/ -- B. Braun Medical Inc. (B. Braun) has entered into a settlement agreement in the amount of $14.7 million with the Department of Justice to resolve a long-standing dispute relating to pricing information published by third parties for certain pharmaceutical products manufactured by B. Braun. The matter was part of an industry-wide investigation arising out of a qui tam action filed under seal in the Southern District of Florida in 1995 by Ven-a-Care of the Florida Keys against B. Braun's predecessor in interest, McGaw, Inc.
The settlement resolves all disputes between B. Braun and the federal government, and after 15 years, B. Braun is happy to have this matter behind it. B. Braun denies all allegations of wrongdoing and has entered into the settlement agreement to avoid excessive ongoing legal costs. B. Braun complies with government laws and regulations and operates under a robust compliance program to ensure continual compliance. As such, B. Braun was not required to enter into a corporate integrity agreement as part of the settlement.
About B. Braun
B. Braun is a leading manufacturer of infusion therapy and pain management products with an environmentally-friendly focus. Guided by the company's "Sharing Expertise®" philosophy, B. Braun addresses the critical issues of infection prevention, medication safety and environmental responsibility by promoting best practices that help clinicians reduce medication errors, prevent healthcare-acquired infections (HAIs) and achieve sustainability objectives.
Consistently recognized by Frost & Sullivan and KLAS for its medical technology and support services, B. Braun employees share their knowledge with colleagues and customers to improve working processes in hospitals and medical practices and to enhance the safety of patients and healthcare professionals. For more information, call 800-227-2862, email us at firstname.lastname@example.org or visit B. Braun at www.bbraunusa.com.
SOURCE B. Braun Medical Inc.